About Hemogenyx Pharmaceuticals (LON:HEMO)
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning; and Hu-PHEC, a cell therapy product for bone marrow/hematopoietic stem cells transplantation. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolLON:HEMO
CUSIPN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-44.09%
Return on Assets-36.07%
Miscellaneous
EmployeesN/A
Outstanding Shares356,040,000
Hemogenyx Pharmaceuticals (LON:HEMO) Frequently Asked Questions
What is Hemogenyx Pharmaceuticals' stock symbol?
Hemogenyx Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HEMO."
Who are some of Hemogenyx Pharmaceuticals' key competitors?
Some companies that are related to Hemogenyx Pharmaceuticals include Avanti Communications (AVN), Filtronic (FTC), Shield Therapeutics (STX), Vipera (VIP), Gulfsands Petroleum (GPX), Tri Star Resources (TSTR), BOTB (Best of the Best PLC) (BOTB), Coretx (COR), Serabi Mining (SRB), Ilika (IKA), ValiRx (VAL), Independent Oil & Gas (IOG), Vernalis (VER), Midatech Pharma (MTPH), SocialGO (TAVI), Ultima (N4P), TechFinancials (TECH) and Safestay (SSTY).
Who are Hemogenyx Pharmaceuticals' key executives?
Hemogenyx Pharmaceuticals' management team includes the folowing people:
- Sir Marc Feldmann, Exec. Chairman
- Dr. Vladislav Sandler Ph.D., Co-Founder & CEO
- Ms. Alexis M. Sandler J.D., Co-Founder & COO
- Mr. Timothy Vincent Le Druillenec FCMA, Fin. Director & Company Sec. (Age 57)
- Mr. Lawrence Pemble, Chief Operating Officer
Has Hemogenyx Pharmaceuticals been receiving favorable news coverage?
Headlines about HEMO stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hemogenyx Pharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the company an impact score of 45.91 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Hemogenyx Pharmaceuticals?
Shares of HEMO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Hemogenyx Pharmaceuticals' stock price today?
One share of HEMO stock can currently be purchased for approximately GBX 3.21.
How big of a company is Hemogenyx Pharmaceuticals?
Hemogenyx Pharmaceuticals has a market capitalization of £10.35 million.
MarketBeat Community Rating for Hemogenyx Pharmaceuticals (HEMO)
MarketBeat's community ratings are surveys of what our community members think about Hemogenyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe HEMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hemogenyx Pharmaceuticals (LON:HEMO) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/23/2016 forward)
Hemogenyx Pharmaceuticals (LON:HEMO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Hemogenyx Pharmaceuticals (LON HEMO) Insider Trading and Institutional Ownership History
Hemogenyx Pharmaceuticals (LON HEMO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/9/2018 | Adrian Beeston | Insider | Buy | 200,000 | GBX 2 | £4,000 | | |
| 10/6/2017 | Adrian Beeston | Insider | Buy | 10,000 | GBX 3 | £300 | | |
(Data available from 1/1/2013 forward)
Hemogenyx Pharmaceuticals (LON HEMO) News Headlines
| Source: |
|
Hemogenyx Pharmaceuticals (LON:HEMO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Hemogenyx Pharmaceuticals (LON HEMO) Stock Chart for Monday, April, 23, 2018
Loading chart…
